PBAC's latest decision on Abiraterone acetate and methylprednisolone: Recommended with restriction (2023). Considered for Metastatic castration-sensitive (hormone-sensitive) prostate cancer in combination with androgen deprivation therapy, for treatment initiation within 6 months of commencing ADT.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2022
Submissions
3
2022 → 2023
Eligible population
Patients with newly diagnosed metastatic castration-sensitive prostate cancer in combination with androgen deprivation therapy, treatment initiated within 6 months of commencing ADT.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
OS
Key trials
LATITUDE, STAMPEDE, PEACE-1
Comparator
apalutamide
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.
Risk sharing
Risk-sharing arrangement in place — Sponsor expects to join the same risk sharing arrangement (RSA) as apalutamide upon listing.
Submission history
Mar 2022: Recommended with restriction · Authority Required
Nov 2022: Recommended with restriction · Authority Required
Jul 2023: Recommended with restriction · Authority Required